scholarly journals Sensitivity and Specificity of New Visual Field Screening Software for Diagnosing Hemianopia

Eye and Brain ◽  
2021 ◽  
Vol Volume 13 ◽  
pp. 231-238
Author(s):  
Supharat Jariyakosol ◽  
Patcharaporn Jaru-ampornpan ◽  
Anita Manassakorn ◽  
Rath Itthipanichpong ◽  
Parima Hirunwiwatkul ◽  
...  
1995 ◽  
Vol 2 (3) ◽  
pp. 117-121 ◽  
Author(s):  
Ivan M. Young ◽  
Julian L. Rait ◽  
Cathy A. Carson ◽  
Hugh R. Taylor
Keyword(s):  

2019 ◽  
pp. 1
Author(s):  
Lukas Mees ◽  
Swati Upadhyaya ◽  
Pavan Kumar ◽  
Sandal Kotawala ◽  
Shankar Haran ◽  
...  

1973 ◽  
Vol 89 (4) ◽  
pp. 287 ◽  
Author(s):  
William J. Rock
Keyword(s):  

2019 ◽  
pp. bjophthalmol-2019-314031 ◽  
Author(s):  
Karam AlRahman Alawa ◽  
Ryan P Nolan ◽  
Elaine Han ◽  
Alejandro Arboleda ◽  
Heather Durkee ◽  
...  

BackgroundCurrent visual field screening machines are bulky and expensive, limiting their accessibility, affordability and use. We report the design and evaluation of a novel, portable, cost-effective system for glaucoma screening using smartphone-based visual field screening using frequency doubling technology (FDT) and a head-mounted display.MethodsNineteen eyes of 10 subjects with new-onset or chronic primary open angle glaucoma were tested and compared with the Humphrey Zeiss FDT and the newly developed Mobile Virtual Perimetry (MVP) FDT with the C-20 testing pattern. Mann-Whitney, Bland-Altman and linear regression analyses were performed to assess statistical difference, agreement and correlation, respectively, between the two devices.ResultsThe average age of the participants was 58±15 years. No statistically significant difference was found between the MVP FDT and the Humphrey Zeiss FDT (p>0.05). Bland-Altman and linear regression analyses demonstrated good agreement and correlation between the two devices.ConclusionThe MVP FDT is a low-cost, portable visual field screening device that produces comparable results to the Humphrey Zeiss FDT and may be used as an easily accessible screening tool for glaucoma.


1995 ◽  
Vol 120 (6) ◽  
pp. 699-708 ◽  
Author(s):  
WILLIAM E. SPONSEL ◽  
◽  
ROBERT RITCH ◽  
ROBERT STAMPER ◽  
EVE J. HIGGINBOTHAM ◽  
...  

1981 ◽  
Vol 92 (4) ◽  
pp. 530-535 ◽  
Author(s):  
Sheldon Rabin ◽  
Peter Kolesar ◽  
Steven M. Podos ◽  
Jacob T. Wilensky

Author(s):  
María Cecilia Moreno ◽  
Brenda Giagante ◽  
Patricia Saidon ◽  
Silvia Kochen ◽  
Jorge Benozzi ◽  
...  

ABSTRACT:Objective:The aim of the present study was to assess visual alterations in a population of Argentine patients treated with the antiepileptic drug vigabatrin.Methods:Twenty patients receiving vigabatrin and 15 patients receiving carbamazepine were examined with automated perimetry using a Humphrey 120-point full screening strategy. In addition, scotopic flash electroretinograms were performed.Results:Of 20 patients treated with vigabatrin, two were unable to cooperate with testing. Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40° of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.Conclusions:Visual field defects among patients on vigabatrin therapy may occur with a higher frequency than previously recognized. The Humphrey 120-points full field screening test and electroretinography are useful tools to assess the visual dysfunction associated with vigabatrin.


Sign in / Sign up

Export Citation Format

Share Document